190 related articles for article (PubMed ID: 17105431)
1. Selective modulation of Abeta42 production in Alzheimer's disease: non-steroidal anti-inflammatory drugs and beyond.
Leuchtenberger S; Beher D; Weggen S
Curr Pharm Des; 2006; 12(33):4337-55. PubMed ID: 17105431
[TBL] [Abstract][Full Text] [Related]
2. Gamma-secretase modulation with Abeta42-lowering nonsteroidal anti-inflammatory drugs and derived compounds.
Czirr E; Weggen S
Neurodegener Dis; 2006; 3(4-5):298-304. PubMed ID: 17047371
[TBL] [Abstract][Full Text] [Related]
3. Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain.
Weggen S; Eriksen JL; Sagi SA; Pietrzik CU; Golde TE; Koo EH
J Biol Chem; 2003 Aug; 278(33):30748-54. PubMed ID: 12777371
[TBL] [Abstract][Full Text] [Related]
4. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity.
Weggen S; Eriksen JL; Das P; Sagi SA; Wang R; Pietrzik CU; Findlay KA; Smith TE; Murphy MP; Bulter T; Kang DE; Marquez-Sterling N; Golde TE; Koo EH
Nature; 2001 Nov; 414(6860):212-6. PubMed ID: 11700559
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic potential of gamma-secretase inhibitors and modulators.
Imbimbo BP
Curr Top Med Chem; 2008; 8(1):54-61. PubMed ID: 18220933
[TBL] [Abstract][Full Text] [Related]
6. Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.
Rogers K; Felsenstein KM; Hrdlicka L; Tu Z; Albayya F; Lee W; Hopp S; Miller MJ; Spaulding D; Yang Z; Hodgdon H; Nolan S; Wen M; Costa D; Blain JF; Freeman E; De Strooper B; Vulsteke V; Scrocchi L; Zetterberg H; Portelius E; Hutter-Paier B; Havas D; Ahlijanian M; Flood D; Leventhal L; Shapiro G; Patzke H; Chesworth R; Koenig G
Mol Neurodegener; 2012 Dec; 7():61. PubMed ID: 23249765
[TBL] [Abstract][Full Text] [Related]
7. Biochemical characterization of the gamma-secretase activity that produces beta-amyloid peptides.
Zhang L; Song L; Terracina G; Liu Y; Pramanik B; Parker E
Biochemistry; 2001 Apr; 40(16):5049-55. PubMed ID: 11305921
[TBL] [Abstract][Full Text] [Related]
8. Presenilin-1 L166P mutant human pluripotent stem cell-derived neurons exhibit partial loss of γ-secretase activity in endogenous amyloid-β generation.
Koch P; Tamboli IY; Mertens J; Wunderlich P; Ladewig J; Stüber K; Esselmann H; Wiltfang J; Brüstle O; Walter J
Am J Pathol; 2012 Jun; 180(6):2404-16. PubMed ID: 22510327
[TBL] [Abstract][Full Text] [Related]
9. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.
Eriksen JL; Sagi SA; Smith TE; Weggen S; Das P; McLendon DC; Ozols VV; Jessing KW; Zavitz KH; Koo EH; Golde TE
J Clin Invest; 2003 Aug; 112(3):440-9. PubMed ID: 12897211
[TBL] [Abstract][Full Text] [Related]
10. Dual-specificity phosphatase 26 (DUSP26) stimulates Aβ42 generation by promoting amyloid precursor protein axonal transport during hypoxia.
Jung S; Nah J; Han J; Choi SG; Kim H; Park J; Pyo HK; Jung YK
J Neurochem; 2016 Jun; 137(5):770-81. PubMed ID: 26924229
[TBL] [Abstract][Full Text] [Related]
11. gamma-Secretase as a therapeutic target in Alzheimer's disease.
Guardia-Laguarta C; Pera M; Lleó A
Curr Drug Targets; 2010 Apr; 11(4):506-17. PubMed ID: 20015011
[TBL] [Abstract][Full Text] [Related]
12. Development and mechanism of γ-secretase modulators for Alzheimer's disease.
Crump CJ; Johnson DS; Li YM
Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767
[TBL] [Abstract][Full Text] [Related]
13. Advances in gamma-secretase modulation.
Pissarnitski D
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
[TBL] [Abstract][Full Text] [Related]
14. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease.
Imbimbo BP
Expert Opin Investig Drugs; 2004 Nov; 13(11):1469-81. PubMed ID: 15500394
[TBL] [Abstract][Full Text] [Related]
15. Possible mechanisms of action of NSAIDs and related compounds that modulate gamma-secretase cleavage.
Kukar T; Golde TE
Curr Top Med Chem; 2008; 8(1):47-53. PubMed ID: 18220932
[TBL] [Abstract][Full Text] [Related]
16. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
17. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
Imbimbo BP; Giardina GA
Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
[TBL] [Abstract][Full Text] [Related]
18. CTF1-51, a truncated carboxyl-terminal fragment of amyloid precursor protein, suppresses the effects of Aβ42-lowering γ-secretase modulators.
Watahiki H; Yagishita S; Futai E; Ishiura S
Neurosci Lett; 2012 Sep; 526(2):96-9. PubMed ID: 22940081
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of Rho-kinase modulate amyloid-beta (Abeta) secretion but lack selectivity for Abeta42.
Leuchtenberger S; Kummer MP; Kukar T; Czirr E; Teusch N; Sagi SA; Berdeaux R; Pietrzik CU; Ladd TB; Golde TE; Koo EH; Weggen S
J Neurochem; 2006 Jan; 96(2):355-65. PubMed ID: 16300630
[TBL] [Abstract][Full Text] [Related]
20. Retrograde transport of γ-secretase from endosomes to the trans-Golgi network regulates Aβ42 production.
Kanatsu K; Hori Y; Ebinuma I; Chiu YW; Tomita T
J Neurochem; 2018 Oct; 147(1):110-123. PubMed ID: 29851073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
